Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- Innovative portfolio growth is strong and expected to continue well beyond 2027. - AUSTEDO sales target reiterated: over $2.5 billion in 2027, with peak sales exceeding $3 billion. - AJOVY showing steady growth and market share gains despite late entry. - Olanzapine LAI launch expected to open significant global opportunity with unmet medical need. - Biosimilar portfolio expanding impact, contributing to U.S. - Teva targets over $2.5 billion in sales from its innovative portfolio by 2027, driven by products like AUSTEDO and new launches such as olanzapine LAI. - The company aims for mid-single-digit revenue growth by 2027. - Operating margin is expected to improve to 30% by 2027, up from about 26% in 2025, driven by portfolio shift to higher-margin innovative products and $700 million cost savings from transformation programs. - Non-GAAP EPS showed slight growth ($0.53 in Q1 2026 vs.
From Teva Pharmaceutical Industries Limited's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Innovative portfolio growth is strong and expected to continue well beyond 2027.
- AUSTEDO sales target reiterated: over $2.5 billion in 2027, with peak sales exceeding $3 billion.
- AJOVY showing steady growth and market share gains despite late entry.
- Olanzapine LAI launch expected to open significant global opportunity with unmet medical need.
- Biosimilar portfolio expanding impact, contributing to U.S. generics growth.
- Generics revenue expected to be stable excluding the loss of generic Revlimid.
- Emalex acquisition expected to contribute meaningfully post-launch in 2027 with approx. 80% gross margin.
- Pipeline milestones and new launches could add up to over $10 billion in peak sales.
2 more points from Teva Pharmaceutical Industries Limited's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Teva Pharmaceutical Industries Limited said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Teva is continuing to invest organically in its innovative portfolio and pipeline as part of its Pivot to Growth Strategy.
- The company plans to execute thoughtful and accretive business development, with 1-2 deals in the hundreds of millions range expected in the short term.
- Emalex acquisition represents a strategic investment aligned with their CNS franchise, expected to drive revenue growth starting in 2027 and margin expansion from 2028.
- Teva is also planning a share repurchase program to enhance shareholder value while preserving financial flexibility for ongoing investments.
2 more points from Teva Pharmaceutical Industries Limited's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Teva Pharmaceutical Industries Limited said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Teva Pharmaceutical Industries Limited's call on order book
Create a free account to keep reading this call
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Teva Pharmaceutical Industries Limited and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Teva Pharmaceutical Industries Limited Q2 FY26 results?
- Innovative portfolio growth is strong and expected to continue well beyond 2027. - AUSTEDO sales target reiterated: over $2.5 billion in 2027, with peak sales exceeding $3 billion. - AJOVY showing steady growth and market share gains despite late entry. - Olanzapine LAI launch expected to open significant global opportunity with unmet medical need. - Biosimilar portfolio expanding impact, contributing to U.S. - Teva targets over $2.5 billion in sales from its innovative portfolio by 2027, driven by products like AUSTEDO and new launches such as olanzapine LAI. - The company aims for mid-single-digit revenue growth by 2027. - Operating margin is expected to improve to 30% by 2027, up from about 26% in 2025, driven by portfolio shift to higher-margin innovative products and $700 million cost savings from transformation programs. - Non-GAAP EPS showed slight growth ($0.53 in Q1 2026 vs.
What is Teva Pharmaceutical Industries Limited share price analysis?
Teva Pharmaceutical Industries Limited currently shows a neutral. The stock trades at a P/E of 25.8 with a market cap of $40,196. Investors should review the full earnings analysis for detailed insights.
Is Teva Pharmaceutical Industries Limited planning capital expenditure?
- Teva is continuing to invest organically in its innovative portfolio and pipeline as part of its Pivot to Growth Strategy.
Keep Teva Pharmaceutical Industries Limited on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.